PDCD1LG2 and neoplasm: Anti-PD-L2-treated mice displayed significant reduction in the growth of tumor volume over the entire assay period and tumor weight at the end point in subcutaneous models compared with control antibody-treated mice, although there was no significant difference between the anti-PD-L1 and anti-PD-L2 treated groups (Fig. 9B).